Group 1 - The core viewpoint of the article highlights that United Chemical (SZ 301209) held its 10th meeting of the second board session on October 24, 2025, to review the proposal for the third quarter report of 2025 [1] - For the fiscal year 2024, United Chemical's revenue composition is reported to be 99.92% from chemicals and 0.08% from other businesses [1] - As of the time of reporting, United Chemical has a market capitalization of 9.6 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have generated $80 billion in overseas licensing this year, indicating a robust performance in the biopharmaceutical secondary market [1] - A dialogue with Lu Gang, a partner at Chuangdong Investment, reveals that while the biopharmaceutical secondary market is thriving, the primary market is facing challenges in fundraising [1]
联合化学：10月24日召开董事会会议